Olfr571 Inhibitors
Olfr571, a prominent member of the olfactory receptor family, plays a pivotal role in the intricate process of odorant perception. As a G-protein-coupled receptor (GPCR), Olfr571 shares a common structural framework with neurotransmitter and hormone receptors, characterized by a 7-transmembrane domain structure. Its function is embedded in the recognition and transduction of olfactory signals, contributing to the initiation of a neuronal response that culminates in the perception of specific smells. Olfactory receptors, including Olfr571, arise from single coding-exon genes and form the largest gene family in the genome. The nomenclature assigned to olfactory receptor genes and proteins is organism-specific, independent of other organisms.
Inhibition of Olfr571 involves the modulation of specific signaling pathways associated with its function. Chemical inhibitors disrupt these pathways, leading to altered expression and function of Olfr571. For instance, inhibitors targeting voltage-gated sodium channels, NMDA glutamate receptors, mitochondrial electron transport, calcium channels, TGF-β receptors, MAPK/ERK pathways, PI3 kinase signaling, potassium channels, EGFR signaling, CaMK signaling, calcium homeostasis, and c-Raf signaling impact Olfr571 indirectly by influencing the respective cellular processes. The diverse mechanisms of inhibition shed light on the complexity of olfactory signal transduction, offering insights into potential strategies for manipulating the function of Olfr571 and, by extension, the broader olfactory receptor system. These inhibitors provide valuable tools for experimental investigations aimed at deciphering the intricate molecular and cellular mechanisms underlying olfactory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $97.00 | 2 | |
NMDA glutamate receptor antagonist affecting Olfr571 indirectly. APV (D-AP5) disrupts NMDA receptor activity, modulating glutamatergic signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
Antimycin A | 1397-94-0 | sc-202467 sc-202467A sc-202467B sc-202467C | 5 mg 10 mg 1 g 3 g | $55.00 $63.00 $1675.00 $4692.00 | 51 | |
Complex III inhibitor influencing Olfr571 indirectly. Antimycin A disrupts mitochondrial electron transport, modulating cellular metabolism and consequently leading to altered expression and function of Olfr571. | ||||||
ω-Agatoxin IVA | 145017-83-0 | sc-302015 | 100 µg | $463.00 | ||
P/Q-type calcium channel blocker affecting Olfr571 indirectly. Agatoxin IVA disrupts calcium channel activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
TGF-β receptor inhibitor affecting Olfr571 through the TGF-β signaling pathway. LY364947 disrupts TGF-β receptor activity, leading to altered expression and function of Olfr571 as a downstream consequence of pathway inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor affecting Olfr571 through the MAPK/ERK pathway. PD98059 disrupts the MAPK/ERK signaling cascade, leading to altered expression and function of Olfr571 as a downstream consequence of pathway inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3 kinase inhibitor influencing Olfr571 through the PI3 kinase signaling pathway. LY294002 disrupts PI3 kinase activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Potassium channel blocker affecting Olfr571 indirectly. Clotrimazole disrupts potassium channel activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor influencing Olfr571 through the EGFR signaling pathway. Gefitinib disrupts EGFR activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
CaMK inhibitor affecting Olfr571 through the CaMK signaling pathway. KN-93 disrupts CaMK activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA inhibitor affecting Olfr571 through calcium homeostasis. Thapsigargin disrupts SERCA activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr571. | ||||||